SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for ...

As global markets experience a rebound fueled by easing core U.S. inflation and strong bank earnings, the focus has shifted to how growth stocks are navigating these conditions. In this environment, ...

Korea's government formed a national bio committee to elevate its bio industry by 2035, focusing on investment and production ...

Press releaseGenethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of ...